



## A new look for 2006

*M. McLean MD*

Welcome to the penultimate edition of *Current Oncology* for 2005, at a time when we are introducing further changes as the journal metamorphoses into its new look for 2006.

The new “Aims and Scope” will underscore our determination to remain Canada’s major oncology publication. We urge you to review these guidelines before considering a submission. And when your article is ready, consider our online submission option, which is about to go live at [www.current-oncology.com](http://www.current-oncology.com). Authors who submit through that site will be able to monitor their manuscript through the peer review process.

The Editorial Board continues to expand, with new journal subsections being overseen by dedicated members of the editorial team. The new subsections include “Integrative Therapies for Oncology” (Stephen Sagar), “Medical Ethics” (Mark Handelman), “Medical Physics” (Jan Seuntjens), “News and Developments in Oncology” (Richard Ablin and Phil Gold), “Nutrition” (Teri Langlois), and “Surgical Oncology” (Fred Saad).

In this issue you will find “Bone complications in prostate cancer: current and future role of bisphosphonates” by Fred Saad, “Rationale for extended adjuvant letrozole after five years of tamoxifen in postmenopausal oestrogen receptor-positive women with early-stage breast cancer” by Heather McArthur and Hagen Kennecke, “Integrative oncology for comprehensive cancer centres: definitions, scope, and policy” by Stephen Sagar and Barrie Cassileth, and following on from a previous review article, “Lung cancer trends. Part 2: Beyond North America” by Patricia Tai and Edward Yu.

We will also soon be publishing a new *Guide for Breast Cancer* in view of the changes in the management options for breast-cancer patients—specifically the postmenopausal oestrogen receptor-positive group for whom the aromatase inhibitors appear to offer some very solid progress. We hope that the new Guide will be enclosed as a supplement with the present issue.

Again, please consider your journal for manuscript submissions. We look forward to hearing from you.